| Drug General Information |
| Drug ID |
D0ZH1U
|
| Former ID |
DNC005110
|
| Drug Name |
TYRPHOSTIN AG-1478
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H14ClN3O2
|
| InChI |
InChI=1S/C16H14ClN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)
|
| InChIKey |
GFNNBHLJANVSQV-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
523974, 3267095, 5600223, 8033257, 8151403, 11111880, 11114011, 11120225, 11120713, 11121201, 11121455, 11121935, 11147308, 11362524, 11365086, 11367648, 11370319, 11370320, 11373249, 11375810, 11382272, 11437777, 12024897, 14801206, 17405683, 24278735, 26527902, 26752149, 26752150, 26759702, 29221232, 47290912, 47290913, 47588775, 47588776, 47662031, 48184767, 48258972, 49635532, 50104794, 50104795, 53778233, 53787589, 53800470, 57321117, 80516749, 85231256, 85267415, 85787241, 85787738
|
| Target and Pathway |
| Target(s) |
Epidermal growth factor receptor |
Target Info |
Inhibitor |
[2]
|
|---|
| Mitogen-activated protein kinase 14 |
Target Info |
Inhibitor |
[3]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Dorso-ventral axis formation
|
|
Focal adhesion
|
|
Adherens junction
|
|
Gap junction
|
|
Regulation of actin cytoskeleton
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Oxytocin signaling pathway
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Hepatitis C
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Bladder cancer
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancerhsa04010:MAPK signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Adrenergic signaling in cardiomyocytes
|
|
VEGF signaling pathway
|
|
Osteoclast differentiation
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Platelet activation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
T cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
Neurotrophin signaling pathway
|
|
Retrograde endocannabinoid signaling
|
|
Dopaminergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
Progesterone-mediated oocyte maturation
|
|
Prolactin signaling pathway
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Influenza A
|
|
Epstein-Barr virus infection
|
|
NetPath Pathway
|
IL4 Signaling Pathway
|
|
EGFR1 Signaling PathwayNetPath_17:IL5 Signaling Pathway
|
|
FSH Signaling Pathway
|
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Cadherin signaling pathway
|
|
EGF receptor signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway
|
|
Angiogenesis
|
|
B cell activation
|
|
EGF receptor signaling pathway
|
|
FGF signaling pathway
|
|
Interferon-gamma signaling pathway
|
|
Oxidative stress response
|
|
Parkinson disease
|
|
TGF-beta signaling pathway
|
|
Toll receptor signaling pathway
|
|
VEGF signaling pathway
|
|
Ras Pathway
|
|
p53 pathway feedback loops 2
|
|
p38 MAPK pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
Signaling events mediated by PTP1B
|
|
Arf6 signaling events
|
|
Signaling events mediated by TCPTP
|
|
Thromboxane A2 receptor signaling
|
|
SHP2 signaling
|
|
Regulation of Telomerase
|
|
EGF receptor (ErbB1) signaling pathway
|
|
EGFR-dependent Endothelin signaling events
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Direct p53 effectors
|
|
ErbB1 downstream signaling
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
E-cadherin signaling in keratinocytes
|
|
ErbB receptor signaling network
|
|
Internalization of ErbB1
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
a6b1 and a6b4 Integrin signaling
|
|
Syndecan-3-mediated signaling eventsendothelinpathway:Endothelins
|
|
BCR signaling pathway
|
|
p73 transcription factor network
|
|
p38 MAPK signaling pathway
|
|
Atypical NF-kappaB pathway
|
|
IL4-mediated signaling events
|
|
CD40/CD40L signaling
|
|
IL12-mediated signaling events
|
|
Regulation of p38-alpha and p38-beta
|
|
CDC42 signaling events
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
FAS (CD95) signaling pathway
|
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
Glucocorticoid receptor regulatory network
|
|
IL2-mediated signaling events
|
|
Rapid glucocorticoid signaling
|
|
Regulation of Androgen receptor activity
|
|
ATF-2 transcription factor network
|
|
IL6-mediated signaling events
|
|
p38 signaling mediated by MAPKAP kinases
|
|
Retinoic acid receptors-mediated signaling
|
|
CXCR3-mediated signaling events
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
EPO signaling pathway
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
p53 pathway
|
|
S1P2 pathway
|
|
Trk receptor signaling mediated by the MAPK pathway
|
|
VEGFR3 signaling in lymphatic endothelium
|
|
FGF signaling pathway
|
|
RAC1 signaling pathway
|
|
Regulation of retinoblastoma protein
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
|
|
SHC1 events in ERBB2 signaling
|
|
PLCG1 events in ERBB2 signaling
|
|
PIP3 activates AKT signaling
|
|
GRB2 events in EGFR signaling
|
|
GAB1 signalosome
|
|
SHC1 events in EGFR signaling
|
|
EGFR downregulation
|
|
GRB2 events in ERBB2 signaling
|
|
PI3K events in ERBB2 signaling
|
|
EGFR Transactivation by Gastrin
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
Constitutive Signaling by EGFRvIII
|
|
RAF/MAP kinase cascadeR-HSA-168638:NOD1/2 Signaling Pathway
|
|
p38MAPK events
|
|
ERK/MAPK targets
|
|
Activation of PPARGC1A (PGC-1alpha) by phosphorylation
|
|
Oxidative Stress Induced Senescence
|
|
CDO in myogenesis
|
|
DSCAM interactions
|
|
ADP signalling through P2Y purinoceptor 1
|
|
Platelet sensitization by LDL
|
|
VEGFA-VEGFR2 Pathway
|
|
activated TAK1 mediates p38 MAPK activation
|
|
Activation of the AP-1 family of transcription factors
|
|
KSRP (KHSRP) binds and destabilizes mRNA
|
|
WikiPathways
|
ErbB Signaling Pathway
|
|
Regulation of Actin Cytoskeleton
|
|
EGF/EGFR Signaling Pathway
|
|
MAPK Signaling Pathway
|
|
Focal Adhesion
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
|
|
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
|
|
Bladder Cancer
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
Signaling by ERBB4
|
|
Signaling by ERBB2
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
PIP3 activates AKT signaling
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Aryl Hydrocarbon Receptor
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Gastric cancer network 2
|
|
AGE/RAGE pathway
|
|
Signaling Pathways in Glioblastoma
|
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Signaling by EGFR
|
|
L1CAM interactionsWP75:Toll-like receptor signaling pathway
|
|
Monoamine Transport
|
|
Serotonin HTR1 Group and FOS Pathway
|
|
TCR Signaling Pathway
|
|
Senescence and Autophagy in Cancer
|
|
Interferon type I signaling pathways
|
|
Insulin Signaling
|
|
MAPK Cascade
|
|
Oxidative Stress
|
|
p38 MAPK Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Kit receptor signaling pathway
|
|
Cardiac Hypertrophic Response
|
|
MAP kinase activation in TLR cascade
|
|
Regulation of mRNA Stability by Proteins that Bind AU-rich Elements
|
|
Structural Pathway of Interleukin 1 (IL-1)
|
|
JAK/STAT
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Alpha 6 Beta 4 signaling pathway
|
|
Cardiac Progenitor Differentiation
|
|
BDNF signaling pathway
|
|
Oncostatin M Signaling Pathway
|
|
Parkinsons Disease Pathway
|
|
Corticotropin-releasing hormone
|
|
B Cell Receptor Signaling Pathway
|
|
Prostate Cancer
|
|
TSLP Signaling Pathway
|
|
TWEAK Signaling Pathway
|
|
FSH signaling pathway
|
|
Leptin signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
miR-targeted genes in leukocytes - TarBase
|
|
IL-1 signaling pathway
|
|
Signal amplification
|
|
Platelet homeostasis
|
|
NGF signalling via TRKA from the plasma membrane
|
|
Myogenesis
|
|
DSCAM interactions
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Angiogenesis
|
|
Physiological and Pathological Hypertrophy of the Heart
|
|
Regulation of toll-like receptor signaling pathway
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4862). |
|---|
| REF 2 | J Med Chem. 1999 Mar 25;42(6):1018-26.Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. |
|---|
| REF 3 | Bioorg Med Chem Lett. 2004 Nov 1;14(21):5389-94.Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. |
|---|
